Research Progress on Predictive Biomarkers of Immunotherapy Efficacy in Non-small Cell Lung Cancer
10.3779/j.issn.1009-3419.2024.106.12
- VernacularTitle:非小细胞肺癌免疫治疗疗效的预测生物标志物研究进展
- Author:
SUN TIANSHENG
1
;
CHEN ZHANG
;
WEI KUNCHEN
;
TANG HAO
Author Information
1. 200003 上海,海军军医大学第二附属医院呼吸与危重症医学科
- Keywords:
Lung neoplasms;
Immunotherapy;
Tumor mutational burden;
Biomarker;
Prognostication
- From:
Chinese Journal of Lung Cancer
2024;27(6):459-465
- CountryChina
- Language:Chinese
-
Abstract:
Lung cancer is one of the most common malignant tumors in the world,of which non-small cell lung cancer(NSCLC)is the majority.The emergence of immune checkpoint inhibitors(ICIs)has greatly changed the treatment strategy of NSCLC and improved the prognosis of patients.However,in reality,only a small number of patients can achieve long-term benefit.Therefore,the identification of reliable predictive biomarkers is essential for the selection of treatment mo-dalities.With the development of molecular biology and genome sequencing technology in recent years,as well as the in-depth understanding of tumor and its host immune microenvironment,research on biomarkers has emerged in an endless stream.This review focuses on the predictive biomarkers of immunotherapy efficacy in NSCLC,in order to provide some guidance for precision immunotherapy.
